Sort   by:  
 Page size 
GenomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (E2F1 ChIP-seq)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36614 | biostudies-arrayexpress
GenomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (cMyc ChIP-seq)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-37617 | biostudies-arrayexpress
TranscriptomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (xenografts)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36433 | biostudies-arrayexpress
TranscriptomicsHes6 expression is controlled by c-Myc and the AR to promote E2F1 activity and poor outcome in castrate-resistant prostate cancer (LNCaP)
Hes6 is a transcription co-factor that is associated with stem cell characteristics in neural tissue, but its role in cancer remains uncertain. Here we show that Hes6 is controlled by c-Myc and the AR and can drive castration resistance in xenografts of the androgen-dependent LNCaP prostate cancer c...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36434 | biostudies-arrayexpress
GenomicsHes6 drives a critical AR transcriptional program to induce castration resistant prostate cancer through activation of an E2F1-mediated cell cycle network
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance, other factors such as c-Myc and the E2F family also play a role in later stage disease. Here we show that Hes6 is up-regulated in aggressive human prost...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-49832 | biostudies-arrayexpress
TranscriptomicsHes6 drives a network with therapeutic potential in castrate-resistant prostate cancer
Castrate-resistant prostate cancer (CRPC) is poorly characterized and heterogeneous and while the androgen receptor (AR) is of singular importance in early prostate cancer, other factors such as c-Myc and the E2F family also play a role in later stage disease. Hes6 is a transcription co-factor that ...
ORGANISM(S): Homo sapiens 
2014-04-17 | E-GEOD-36526 | biostudies-arrayexpress
GenomicsThe androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man
The androgen receptor (AR) is the major transcriptional driver of prostate cell growth in man. For the first time, we define AR targets in prostate cancer (PC) tissue representing progression from treatment-naive to castrate-resistant disease (CRPC). We employed chromatin immunoprecipitation with hi...
ORGANISM(S): Homo sapiens 
2013-01-04 | E-GEOD-28219 | biostudies-arrayexpress
GenomicsOrigins and functional consequence of somatic mitochondrial DNA mutations
Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mitochondrial DNA (mtDNA) are unclear. Here, we analysed soma...
EGAS00001000968 | EGA
GenomicsCRUK-ICGC Prostate Cancer Group Study
Prostate cancer somatic genomic sequencing data generated from 2011 onwards under auspices of the International Cancer Genome Consortium Prostate Cancer UK consortium (CRUK-ICGC Prostate Group), co-led by Colin Cooper and Ros Eeles, with other Principal Investigators (Brewer, Neal, Bova, McDermott, ...
EGAS00001000262 | EGA
UnknownEffect of mutation order on myeloproliferative neoplasms.
Not available
S-EPMC4660033 | biostudies-literature
Sort   by:  
 Page size